Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham heart study beyond LDL-C and non-HDL-C

European Journal of Preventive Cardiology

Volumn 22, Issue 10, 2015, Pages 1321-1327

  Pencina, Michael J ^a,b   D'Agostino, Ralph B ^c   Zdrojewski, Tomasz ^d   Williams, Ken ^e   Thanassoulis, George ^f   Furberg, Curt D ^g   Peterson, Eric D ^h   Vasan, Ramachandran S ^b   Sniderman, Allan D ⁱ  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

^c USA   (United States)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e KenAnCo Biostatistics   (United States)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

ApoB; CAD; Discordance; Guidelines; Non HDL C; Risk factor; Risk prediction

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100; BIOLOGICAL MARKER; CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORONARY RISK; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CORONARY DISEASE; DECISION SUPPORT SYSTEM; DISEASE FREE SURVIVAL; DYSLIPIDEMIAS; KAPLAN MEIER METHOD; MASSACHUSETTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR;

ADULT; AGED; APOLIPOPROTEIN B-100; BIOMARKERS; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY DISEASE; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; DYSLIPIDEMIAS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MASSACHUSETTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84942884643     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487315569411     Document Type: Article

References (27)

1. Tabas I, Williams KJ and Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications. Circulation 2007;116:1832-1442.
2. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirty-person/ten-country panel. J Intern Med 2006;259:247-258.
3. Krauss RM and Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982;23:97-104.
4. Teng B, Thompson GR, Sniderman AD, et al. Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia. Proc Natl Acad Sci USA 1983;80:6662-6666.
5. Chapman MJ, Laplaud PM, Luc G, et al. Further resolution of the low density lipoprotein spectrum in normal human plasma: Physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res 1988;29:442-458.
6. Sniderman AD, St-Pierre AC, Cantin B, et al. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003;91:1173-1177.
7. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007;298:776-785.
8. Friedewald WT, Levy RI and Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
9. Cox DR. Regression models and life tables. JRStat Soc B 1972;34:187-220.
10. Pencina MJ and D'Agostino RB. Overall C as a measure of discrimination in survival analysis: Model specific population value and confidence interval estimation. Stat Med 2004;23:2109-2123.
11. Pencina MJ, D'Agostino Sr RB, D'Agostino Jr RB, et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172; discussion 207-212.
12. Demler OV, Pencina MJ and D'Agostino Sr RB. Misuse of DeLong test to compare AUCs for nested models. Stat Med 2012;31:2577-2587.
13. Vickers AJ, Cronin AM and Begg CB. One statistical test is sufficient for assessing new predictive markers. BMC Med Res Methodol 2011;11:13.
14. SAS/STAT 9.2 user's guide, Chapter 3: Introduction to statistical modeling with SAS/STAT software.[S.l.]. Cary, NC: SAS, 2008.
15. Pencina MJ, D'Agostino RB, Pencina KM, et al. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol 2012;176:473-481.
16. Mora S, Buring JE and Ridker PM. Discordance of lowdensity lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation 2014;129:553-561.
17. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - implications for LDL management. J Clin Lipidol 2007;1:583-592.
18. Otvos JD, Mora S, Shalaurova I, et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol 2011;5:105-113.
19. Sniderman AD, Islam S, Yusuf S, et al. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis 2012;225:444-449.
20. Koskinen J, Magnussen CG, Wurtz P, et al. Apolipoprotein B, oxidized low-density lipoprotein, and LDL particle size in predicting the incidence of metabolic syndrome: The Cardiovascular Risk in Young Finns study. Eur J Prev Cardiol 2012;19:1296-1303.
21. Di Angelantonio E, Gao P, Pennells L, et al. Lipidrelated markers and cardiovascular disease prediction. JAMA 2012;307:2499-2506.
22. Sniderman AD, Williams K, Contois JH, et al. A metaanalysis of low-density lipoprotein cholesterol, non-highdensity lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011;4:337-345.
23. Ndumele CE, Matsushita K, Astor B, et al. Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: The ARIC study. Eur J Prev Cardiol 2012;21:866-875.
24. Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: Position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009;55:407-419.
25. Sniderman A, Couture P and De Graaf J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol 2010;6:335-346.
26. Sniderman AD. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: Implications for clinical practice. J Clin Lipidol 2008;1:36-42.
27. Thanassoulis G, Williams K, Ye K, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: A metaanalysis of randomized trials. J Am Heart Assoc 2014;3:e000759.